申请人:Pfizer Inc.
公开号:US04977178A1
公开(公告)日:1990-12-11
Certain substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones are highly potent gabaergic agents, valuable in the treatment of individuals suffering from schizophrenia or reversing the side effects of a previously or concurrently administered neuroleptic agent; or in the treatment of epilepsy. A wider class of substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones, together with 1-phenyl-3-(2-pyrrolidinylidene)-2(1H,3H)-indolones, and homologs thereof, are valuable in the treatment of anxiety.
某些取代的1-苯基-3-(氨基烷基亚甲基)-2(1H,3H)-吲哚酮是高效的GABA能药物,在治疗患有精神分裂症或逆转先前或同时给予的神经阻滞剂药物的副作用方面非常有价值;或在治疗癫痫方面也非常有价值。更广泛的一类取代的1-苯基-3-(氨基烷基亚甲基)-2(1H,3H)-吲哚酮,以及1-苯基-3-(2-吡咯烷亚甲基)-2(1H,3H)-吲哚酮及其同系物,在治疗焦虑方面也非常有价值。